新型冠状病毒肺炎患者使用利巴韦林注射液的用药分析、不良反应及药学监护

Analysis of ribavirin injection, adverse reactions and pharmaceutical care in patients of COVID-19

目的回顾性分析利巴韦林注射液在武汉市第三医院新型冠状病毒肺炎(COVID-19)患者中的使用情况、不良反应及药学监护,以期为抗病毒合理用药提供理论依据。方法借助医院信息系统提取2020年1月1日—2020年3月17日于武汉市第三医院治疗时使用过利巴韦林注射液的32例COVID-19患者的临床资料。对利巴韦林的用药情况、药物不良反应进行分析,并提出药学监护计划。结果利巴韦林的使用存在剂量不足、配制浓度过高、疗程较长、联合用药品种过多及特殊人群用药不适宜的问题,其不良反应发生率较高。结论利巴韦林在治疗COVID-19的使用还有待进一步的规范,临床用药过程中应密切关注不良反应的发生,进一步加强药学监护。

Objective The use, adverse reactions, and pharmaceutical care of Ribavirin Injection in patients with corona virus disease 2019(COVID-19) in The Third Hospital of Wuhan were analyzed retrospectively, so as to provide theoretical basis for the rational use of antiviral drugs.Methods The hospital information system was used to extract the clinical data of 32 cases COVID-19 patients who had used Ribavirin Injection in The Third Hospital of Wuhan from January 1 to March 17, 2020.The situation of ribavirin use and adverse drug reactions were analyzed, and the pharmaceutical care plan was put forward.Results The use of ribavirin has some problems, such as insufficient dose, high concentration of ribavirin, long course of treatment, too many varieties of combined drugs and inappropriate use of drugs in special population, with a high incidence of adverse reactions.Conclusion The use of ribavirin in treatment of COVID-19 remains to be further standardized, and the occurrence of adverse reactions should be closely watched during the clinical medication process to further strengthen pharmaceutical care.